-
GM-CSF monoclonal antibody combined with Yescarta, all CRS events are less than or equal to grade 3!
Time of Update: 2021-05-09
reported that patients in the clinical study ZUMA-19 of the combination therapy of CAR-T therapy Yescarta (axicabtagene ciloleucel, Axi-Cel) and Lenzilumab Positive data, and based on this data plan to initiate a potential registration study.
-
Guidelines for the diagnosis and treatment of multiple myeloma in China (revised in 2020)
Time of Update: 2021-05-08
Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally.
Multiple myeloma (MM) is a malignant disease in which clonal plasma cells proliferate abnormally.
It is the second most common malignant tumor in the blood system in many countries.
-
Why can't human albumin be infused too quickly?
Time of Update: 2021-05-08
reasonReason reasonReason oneReason oneWhen a large amount of albumin is infused, the protein content in the plasma suddenly rises, which causes the plasma colloidal osmotic pressure to rise, and the water in the interstitial space flows into the blood vessels in a large amount, resulting in tissue dehydration.
-
Be wary of hemophilia when these symptoms occur, and avoid taking 3 drugs daily
Time of Update: 2021-05-08
Hemophilia can be divided into mild, intermediate and severe types according to the activity levels of coagulation factors in patients.
5. Genetic testing: It is recommended to perform genetic testing on patients in order to determine the disease-causing genes and provide evidence for carrier testing and prenatal diagnosis in the same family.
-
J Clin Oncol: Phase 3 | Efficacy and safety of lenalidomide combined with R-CHOP regimen in the treatment of ABC DLBCL
Time of Update: 2021-05-08
01366" target="_blank" rel="noopener">ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma .
-
JAMA: The effect of intravenous poloxamer 188 on the duration of painful vascular occlusion in patients with sickle cell anemia
Time of Update: 2021-05-08
In previous clinical studies, poloxamer 188 treatment can shorten the duration of the onset of painful vascular occlusion in SCD patients, especially for children and previously received Hydroxyurea is effective in treating patients.
-
J Clin Oncol: Brentuximab combined with AVD regimen in the treatment of newly diagnosed early-stage Hodgkin's lymphoma with a risk of poor prognosis
Time of Update: 2021-05-08
For a long time, the combined treatment plan has been used as the standard treatment plan for early stage (ES), mass Hodgkin's lymphoma (HL) with a risk of poor prognosis , that is, chemotherapy + radiotherapy.
-
Interpretation of the Guidelines for the Treatment of Acute Leukemia and MDS by Allogeneic Transplantation | CSCO Guidelines Conference 2021
Time of Update: 2021-05-08
Topic 1: Indications and Timeliness 2021 "Guidelines for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Leukemia and Myelodysplastic Syndrome" is divided into multi-level catalogs.
-
[Metz live broadcast] Live broadcast of thrombolysis decision-making for light stroke, Director Zhang Lifang at 19:00 on April 29, registration has the opportunity to receive a physical book!
Time of Update: 2021-05-08
Scan the code and sign up for free!At 19:00 on April 29th, the teacher of the Department of Neurology, Changzhi People’s Hospital, Changzhi Medical College, [Zhang Lifang] gave an online lesson.
-
Nat Commun: 17 prospective studies reveal that blood n-3 fatty acid levels are associated with reduced all-cause mortality
Time of Update: 2021-05-08
A meta-analysis of another observational study found that higher circulating LC n-3 PUFA levels were significantly associated with a lower risk of CHD death.
-
J Clin Oncol: ROCK2 inhibitor berudil can effectively treat refractory chronic graft-versus-host disease
Time of Update: 2021-05-08
A Phase IIa, open-label dose exploratory study " ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease " published in the " Journal of Clinical Oncology " recently , aimed at clarifying Beludi The dose and effect of ER for cGVHD patients who have previously received first-line third-line therapy (LOT).
-
Blood: The long-term efficacy of imiizumab prevention in patients with hemophilia A
Time of Update: 2021-05-07
2020009217" target="_blank" rel="noopener">Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies .
2020009217" target="_blank" rel="noopener">Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies in this message
-
Oxbryta, the first treatment for sickle cell disease, announces latest research results
Time of Update: 2021-05-02
Original Source: Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
-
"Pharmaceutical Speed Reading Club" Ingram Medical's 700 million project exposes doctors to expose the shady of tumor treatment
Time of Update: 2021-05-02
[April 19, 2021/Medical Information List] Jiangxi's domestic bivalent cervical cancer vaccine "starts up" costs only 1,000 yuan ; Puli Pharmaceuticals 500mg levofloxacin tablets obtained drug registration approval; Incorporated 700 million put into construction an annual output of 500,000 Tons of carboxyl-butadiene nitrile latex, 100,000 tons of DOTP project; Wantai Biotech's new crown antigen detection kit was approved to be sold in the German market.
-
Merck evobrutinib has been shown to reduce nerve damage in MS patients...
Time of Update: 2021-05-02
The trial showed that in multiple sclerosis ( In MS) patients, oral, highly selective BTK inhibitor evobrutinib treatment significantly reduced blood neurofilament light chain (NfL) levels, which is a key biomarker of nerve damage and inflammation.
-
Nature predicts the scale of the global market for listed ADC drugs: 2026...
Time of Update: 2021-05-02
Enfortumab vedotin (trade name: Padcev) jointly developed by Seagen/Astellas is a Nectin-4 monoclonal antibody-MMAE conjugate drug and the first ADC to enter the urothelial cancer market.
Trastuzumab duocarmazine, developed by Byondis, is an ADC drug targeting HER2 and is undergoing a phase III clinical study for the treatment of HER2-positive metastatic breast cancer.
-
Abbott's TriClip G4 tricuspid valve repair system obtains EU CE certification
Time of Update: 2021-05-02
A few days ago, Abbott's latest generation of upgraded minimally invasive transcatheter tricuspid valve repair system TriClip G4 has obtained CE mark approval from European regulatory agencies to help prevent blood leakage from the patient's heart tricuspid valve.
-
Purchase with quantity!
Time of Update: 2021-05-02
The three alliances purchase products including disposable sterile syringes, disposable vacuum blood collection tubes, disposable oxygen suction tubes, pre-filled catheter irrigators, disposable urinary catheters, disposable urinary catheters, virus samplers, 9 kinds of low-value medical consumables, including sample release agents and automatic nucleic acid extraction reagents.
-
"Pharmaceutical Speed Reading Society" Eli Lilly's Erbitux new dosing regimen was awarded the U.S. FDA...
Time of Update: 2021-05-02
[April 9th, 2021 / Medical Information List] Zhao Jun, vice chairman and director of Osaikang, resigned; Eli Lilly’s Erbitux new drug regimen was approved by the US FDA; Hutchison Medicine received US$100 million in equity investment; Connoa Biotech submitted The IPO prospectus of the Hong Kong Stock Exchange.
-
85% of patients with early multiple sclerosis have no disease progression Roche CD20 antibody latest...
Time of Update: 2021-05-02
An analysis of interim data from the open-label Phase 3b clinical trial ENSEMBLE showed that 85% of patients with early relapsing-remitting multiple sclerosis (RRMS) had not shown any signs of disease progression after receiving Ocrevus for 48 weeks.
